Müller T - Search Results

1

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.

Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Goetz CG, et al. Among authors: muller t. Mov Disord. 2007 Jan 15;22(2):179-86. doi: 10.1002/mds.21226. Mov Disord. 2007. PMID: 17094088 Clinical Trial.

2

Tolcapone and neurotoxicity in Parkinson's disease.

Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T. Kuhn W, et al. Among authors: muller t. Lancet. 1998 Oct 17;352(9136):1313-4. doi: 10.1016/S0140-6736(05)70527-4. Lancet. 1998. PMID: 9788488 No abstract available.

3

Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.

Russ H, Müller T, Woitalla D, Rahbar A, Hahn J, Kuhn W. Russ H, et al. Among authors: muller t. Naunyn Schmiedebergs Arch Pharmacol. 1999 Dec;360(6):719-20. doi: 10.1007/s002109900168. Naunyn Schmiedebergs Arch Pharmacol. 1999. PMID: 10619191 Clinical Trial.

4

Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.

Müller T, Russ H. Müller T, et al. Expert Opin Pharmacother. 2006 Sep;7(13):1715-30. doi: 10.1517/14656566.7.13.1715. Expert Opin Pharmacother. 2006. PMID: 16925499 Review.

5

Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease.

Hauser RA, Russ H, Haeger DA, Bruguiere-Fontenille M, Müller T, Wenning GK. Hauser RA, et al. Among authors: muller t. Clin Neuropharmacol. 2006 Nov-Dec;29(6):322-30. doi: 10.1097/01.WNF.0000229546.81245.7F. Clin Neuropharmacol. 2006. PMID: 17095895

6

Exercise improves efficacy of levodopa in patients with Parkinson's disease.

Muhlack S, Welnic J, Woitalla D, Müller T. Muhlack S, et al. Among authors: muller t. Mov Disord. 2007 Feb 15;22(3):427-30. doi: 10.1002/mds.21346. Mov Disord. 2007. PMID: 17226855

7

Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.

Müller T, Woitalla D, Russ H, Hock K, Haeger DA. Müller T, et al. J Neural Transm (Vienna). 2007;114(8):1023-6. doi: 10.1007/s00702-007-0718-4. Epub 2007 Apr 10. J Neural Transm (Vienna). 2007. PMID: 17417738

8

[Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].

Ellrichmann G, Russ H, Müller T. Ellrichmann G, et al. Among authors: muller t. Fortschr Neurol Psychiatr. 2007 Jul;75(7):387-96. doi: 10.1055/s-2006-944314. Epub 2006 Nov 17. Fortschr Neurol Psychiatr. 2007. PMID: 17443441 Review. German.

9

Placebo influences on dyskinesia in Parkinson's disease.

Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, Russ H. Goetz CG, et al. Among authors: muller t. Mov Disord. 2008 Apr 15;23(5):700-7. doi: 10.1002/mds.21897. Mov Disord. 2008. PMID: 18175337 Free PMC article.

10

Cysteine elevation in levodopa-treated patients with Parkinson's disease.

Müller T, Kuhn W. Müller T, et al. Mov Disord. 2009 Apr 30;24(6):929-32. doi: 10.1002/mds.22482. Mov Disord. 2009. PMID: 19243072 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,493 results

Search Page

Filters